Translational and clinical immunologyCancer in primary immunodeficiency diseases: Cancer incidence in the United States Immune Deficiency Network Registry
Section snippets
USIDNET registry
The USIDNET registry collects a number of variables on subjects with PIDD including clinical, laboratory, and outcome data, which together provide a health survey of this rare group of subjects. The registry data are based on entries from physicians or their designees from 39 academic institutions in the United States who have institutional review board (IRB)-approved protocols and 5 medical offices that use the USIDNET IRB consent protocol. In addition, patients may enroll themselves, also
Cancer incidence in subjects with PIDD
As of July 1, 2015, 3844 subjects with a PIDD diagnosis were included in the USIDNET registry. To be considered for analysis, subjects needed their PIDD diagnosis and age of last follow-up to be entered into the database by July 1, 2015. Because subjects in the database did not have the age of cancer diagnosis listed, age at last follow-up was used as a surrogate for age of cancer diagnosis. We excluded 186 subjects who did not have the age at last follow-up, which left 3658 subjects in the
Discussion
The USIDNET registry is supported by the National Institutes of Health to enhance the understanding and care of subjects with PIDD. For many years, attempts have been made to evaluate the excess number of malignancy in these subjects. As the USIDNET registry is populated with data on these rare diseases, we undertook an examination of the current registry to gain an up-to-date survey of cancers in PIDD. We observed a 1.42-fold excess relative risk of cancer in subjects with PIDD compared with
References (37)
- et al.
Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning
Blood
(2011) - et al.
Cancer in children with primary immunodeficiency diseases
J Pediatr
(1974) - et al.
Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency?
Blood
(2010) - et al.
Primary immunodeficiencies in the Netherlands: national patient data demonstrate the increased risk of malignancy
Clin Immunol
(2015) - et al.
Morbidity and mortality in common variable immune deficiency over 4 decades
Blood
(2012) - et al.
Prospective study of cancer in patients with hypogammaglobulinaemia
Lancet
(1985) - et al.
Lymphoproliferative disease and cancer among patients with common variable immunodeficiency
Leuk Res
(2015) - et al.
Allergy and risk of hematologic malignancies: associations and mechanisms
Leuk Res
(2014) - et al.
Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation
Blood
(2006) - et al.
GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity
Blood
(2014)
Neoantigens in cancer immunotherapy
Science
Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003
Ann Intern Med
Age at cancer diagnosis among persons with AIDS in the United States
Ann Intern Med
Cancer burden in the HIV-infected population in the United States
J Natl Cancer Inst
Spectrum of cancer risk late after AIDS onset in the United States
Arch Intern Med
Secondary cancers following allogeneic haematopoietic cell transplantation in adults
Br J Haematol
Spectrum of cancer risk among US solid organ transplant recipients
JAMA
Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors
Environ Mol Mutagen
Cited by (162)
Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab
2023, Annals of Allergy, Asthma and ImmunologyInborn errors of immunity in adulthood
2024, Allergy, Asthma and Clinical ImmunologyMultiple-breath washout to detect lung disease in patients with inborn errors of immunity
2024, ERJ Open ResearchINBORN ERRORS OF IMMUNITY AND MALIGNANCY
2024, Current Allergy and Clinical ImmunologyMalignancies and Lymphoproliferations in Children with Primary Immune Deficiency-A Single-center Experience
2024, Journal of Pediatric Hematology/Oncology
Supported by Roswell Park Cancer Institute National Cancer Institute Cancer Center support grants (P30CA016056, 5T32CA108456 [to P.C.M.], NLM K01LM012100 [to K.E.], T32CA085183 [to K.L.S.], R01CA140622 [to S.I.A.], P50 CA159981 [to K.O.], R01CA188900 [to B.H.S. and K.B.M.]), and the United States Immunodeficiency Network and Immune Deficiency Foundation (U24AI086037-06).
This work was presented at the American Society of Clinical Oncology annual meeting in Chicago, IL June 3-7, 2016, as a poster discussion session.
Disclosure of potential conflict of interest: B. Segal's and P. Mayor's institutions received a grant from the National Institutes of Health (NIH) for this work. K. Eng's institution received NIH grant K01LM012100 for this work. K. Singel's institution received a grant from NIH. R. Fuleihan's institution received consultancy fees from CSL Behring and Shire, and payment for lectures from Shire. H. Ochs' institution received a grant from Jeffrey Modell Foundation. F. Bonilla personally received consultancy fees from CSL Behring, Grand Rounds Health Immune Deficiency Foundation, Advance Medical Consultation, Charles River Associates International, Green Cross, American Research Group, Guidepoint Global Advisors, Sarepta, Inc., and Health Resources Services Administration; payment for lectures from Brigham Board Review in Allergy and Immunology (Distance Learning) Course; royalties from UpToDate; and travel expenses from Immune Deficiency Foundation. R. Buckley is employed by Duke University Medical Center. K. Sullivan's institution received USIDNET subcontract from NIH; and K. Sullivan personally received consultancy fees from UpToDate and Immune Deficiency Foundation. Z. Ballas's institution received consultancy fees from Checkmate Pharmaceutical and grants from Checkmate Pharmaceutical for other works, and has a pending patent application using EGF level as a biomarker for response to ipilimumab; Z. Ballas personally received royalties from UpToDate C. Cunningham-Rundles's institute received U24 grant to the Immune Deficiency Foundation for USIDNET. The rest of the authors declare that they have no relevant conflicts of interest.